Folegatti, P., Bittaye, M., Flaxman, A., Lopez, F., Bellamy, D., Kupke, A., . . . Gilbert, S. (2020). Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Elsevier.
Чикаго стиль цитування (17-те видання)Folegatti, PM, et al. Safety and Immunogenicity of a Candidate Middle East Respiratory Syndrome Coronavirus Viral-vectored Vaccine: A Dose-escalation, Open-label, Non-randomised, Uncontrolled, Phase 1 Trial. Elsevier, 2020.
Стиль цитування MLA (9-ме видання)Folegatti, PM, et al. Safety and Immunogenicity of a Candidate Middle East Respiratory Syndrome Coronavirus Viral-vectored Vaccine: A Dose-escalation, Open-label, Non-randomised, Uncontrolled, Phase 1 Trial. Elsevier, 2020.